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Abstract
Malignancies involving the upper and lower airways can be presented as acute and/
or acute-on-chronic life-threatening emergencies. Most of them require intensive care
unit (ICU) admission and acute intervention. Such emergencies include but are not
exhaustive to epistaxis,  massive hemoptysis,  central airways obstruction, postob-
structive  pneumonia,  tracheoesophageal  fistula,  and  pleural  disease.  These  are
frequent consequences of disease, iatrogenicity, and various pleural diseases causing
respiratory  failure.  The  incidence,  physiology,  symptoms,  and  sequelae  of  each
disease  will  be  outlined  in  addition  to  potential  surgical,  pharmacologic,  and
conservative interventions. An anatomical approach from the upper airway, lower
airway, mediastinum, and pleura will be taken. Here, we discuss interventions such
as emergent cautery, nasal packing, emergent airways, and tracheostomy in addition
to a  brief  glance at  other surgical  modalities.  We will  also detail  central  airway
complications  such  as  obstructing  endobronchial  tumors,  massive  hemoptysis,
bronchoscopy, rigid bronchoscopy, stent placement, and other interventions (cautery,
cryotherapy, one-way valves). Finally, pleural disorders such as tension pneumothor-
ax,  bronchopleural  fistulas,  massive  pleural  effusion,  and  hemothorax  will  be
reviewed.
Keywords: respiratory failure, central airway obstruction (CAO), upper airway ob-
struction, epistaxis, massive hemoptysis, stridor, endoluminal disease, malignant
pleural effusion, massive pleural effusion, tension pneumothorax, hemothorax, bron-
chopleural fistula, ENT, interventional pulmonology, cardiothoracic surgery, thoracot-
omy, thoracostomy, intrapleural fibrinolysis
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1. Introduction
As the armamentarium of oncologists continues to improve, so do the outcomes of their
patients. However, morbidity persists and many patients require intensive care unit (ICU) as
a consequence of end-stage disease, multiorgan dysfunction, infection, and airway compro-
mise. This chapter focuses on airway emergencies that are typically experienced in the ICU.
Classification and designation of tumors will not be reviewed. Rather yet, the airway and
mediastinal  burden  of  tumor  will  be  detailed.  We have  organized  the  discussion  in  an
anatomical approach, sequenced as such: upper airway (nasal cavity, pharynx, and larynx),
lower airway (trachea, primary bronchi, and parenchyma), and pleura.
1.1. Upper airway obstruction
We consider upper airway obstruction attributable to cancer a medical emergency. The clinical
manifestations of airway obstruction will depend on the underlying disease, the anatomic
location, acuity, and severity of airway compromise. Primary head and neck tumors causing
upper airway obstruction are perilaryngeal tumors including supraglottic, pharyngeal,
pyriform fossa, periglottic, vocal cord, and subglottic lesions. Almost all (95%) of head and
neck cancers are squamous cell carcinomas [2], and most occur in patients with an extensive
smoking history. Obstruction can occur via mass effect, edema, or hemorrhage. Metastatic
breast, colon, melanoma, sarcoma, lymphoma, and esophageal cancers are also associated with
upper airway obstruction [2]. Certain obstructions can be asymptomatic and can develop
insidiously, making propensity to clinical deterioration unpredictable. Airway salvage and
maintenance of oxygenation is the main interventional objective. In this chapter, we also
emphasize early airway protection and limiting use of paralytics.
1.2. Etiology and pathogenesis
Upper airway obstruction can be classified as functional, anatomic (e.g., squamous cell
carcinoma of larynx), acute, or subacute. Based on the site of obstruction, patients can be
divided into different subclasses including obstructive lesions in and around the larynx, mid-
tracheal obstruction due to retrosternal goiters, and thyroid carcinomas. We highlight a key
respiratory physiologic determinant of airway resistance, Poiseuille’s Law. Simply put, airway
resistance is dependent on airway diameter and turbulence. Thusly, small changes in airway
diameter lead to large changes in resistance of the airflow as the airway resistance is directly
proportional to the length and inversely proportional to the fourth power of the airway radius
[15].
1.3. Diagnosis
If suspected, we suggest an anatomic survey to rule out airway obstruction. Many modalities
are available to the intensivist, such as direct laryngoscopy, bronchoscopy, and flouroscopic
guidance. Our practice is to evaluate the patient starting cephalad and progressing caudad,
both through direct visualization and for establishing a differential diagnosis. Coupling
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underlying medical history and physical exam with appropriate imaging, the treatment plan
should be formulated promptly. With CT imaging of the neck and mediastinal structures, we
are able to identify the extension of disease and its positioning relative to nearby anatomy.
Routine chest radiography in this sense is limited to its two-dimensional depictions and helps
identify tracheal and skeletal abnormalities but mainly helps indicate what next imaging
modality is needed.
1.4. Signs and symptoms
We commonly observe symptoms of upper airway obstruction as respiratory distress,
hoarseness, stridor, facial swelling, or failure to oxygenate with a bag-valve mask. Supraglottic,
subglottic, or cancers of the hypopharynx do not usually cause voice changes and are therefore
diagnosed in late stages. The most common cause of hoarseness is edema of the true vocal
cords. Six weeks of hoarseness in an adult is highly suspicious for a precancerous or cancerous
laryngeal lesion. Although not considered a true emergency, hoarseness warrants thorough
evaluation.
Stridor is defined as a high-pitched wheezing heard during the respiratory cycle, and is usually
more intense during the inspiratory phase. It is appreciated when the airway is at least 5 mm
or 50% of its previous diameter [13, 23]. The most common cancers associated with stridor
from airway obstruction are squamous cell carcinoma of the larynx, trachea, and esophagus.
Pancoast tumors can secondarily cause interstitial edema of the head and neck leading to
airway compromise from superior vena cava (SVC) obstruction.
1.5. Management of upper airway obstruction
The primary objective for an intensivist is to establish and safely provide an airway. Malig-
nancies of the base of the tongue, nasopharynx, pyriform fossa, epiglottis, and vocal cords
will usually require a surgical airway such as tracheotomy or cricothyrotomy. These tu-
mors have a high propensity for bleeding and special precautions must be taken and emer-
gent surgical consultation must be considered. If the airway is amenable to intubation,
smaller-sized endotracheal tubes should be amenable. Long-acting sedatives and muscle
relaxants should be avoided as they predispose airway obstructions to airway collapse and
respiratory failure. Long-term definitive management involved treating the underlying
cause, which is usually treated surgically. However, the majority of patients with malignant
airway obstructions will be unresectable due to locally advanced disease, metastatic dis-
ease, or poor surgical candidacy.
2. Epistaxis and Post Operative Hematoma
Epistaxis, or nosebleed, occurs in up to 10% of patients with advanced cancer. Common causes
of epistaxis in the cancer population are intranasal neoplasms, polyps, leukemia, and coagu-
lopathic disorders including thrombocytopenia secondary to malignancy, medication, or
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anticoagulation. It is frequently associated with squamous cell carcinoma, melanoma, and
papillomatous lesions [1]. Although rare, nasal cavities can also be a source of metastasis [2].
Epistaxis is anatomically classified as being located in the anterior or posterior nasopharynx.
Occasionally, patients might present with severe, life-threatening epistaxis that arises from the
larger vessels in the posterior and superior nasal cavity. This bleeding can compromise the
airway and results in respiratory failure. Although a thorough medical history and physical
exam is necessary, rapid epistaxis can become a life-threatening event. If time allows for
quantification of bleeding, the duration and/or a history of a bleeding disorder should be taken
into account. Despite the profound incidence of all-cause epistaxis, a societal guideline on
management does not exist. Our approach, as in all institutions, is evidence-based neverthe-
less [3]. A stepwise approach is pertinent and consists of hemostasis conservative measures,
localized tamponade, and surgical specialist intervention [4].
2.1. Anterior epistaxis
Patients with active or frequent nosebleeds should be evaluated for an anterior source of
bleeding. Approximately 90% of anterior nosebleeds occur at Kiesselbach’s plexus or Little’s
area. As a consequence, most of the blood exits anteriorly. This is supplied from the external
carotid artery, the superior labial branch of the facial artery, and the terminal branch of the
sphenopalantine artery. The internal carotid also supplies the anterior and posterior ethmoidal
arteries.
Visualizing the bleeding with nasal speculum/thudicum with a light source is the initial
approach but is inferior to direct rhinoscopy/nasendoscopy [4–6]. If blood obfuscates visuali-
zation, irrigation or suctioning techniques should be pursued. Applying direct mechanical
pressure may control bleeding, by manually occluding the anterior aspect of the nose in a
pincer fashion while leaning forward or applying pressure with an ice pack for 15 min. This
serves to tamponade the lesion and allows for platelet aggregation and clot activation. Patients
should be kept upright [7].
Nasal packing is a skill that the intensivist should be comfortable in administering while
awaiting otolaryngology evaluation. Risk of nasal packing includes but is not limited to tissue
necrosis, obstruction, and infection. The anterior nares should be packed with Merocel®
tampon or gauze soaked with 4% lidocaine and oxymetazoline to promote vasoconstriction.
There is little data, however, showing oxymetazoline’s role in hastening hemostasis. Friable
lesions causing epistaxis can bleed even more with treatment intervention. If a bleeding vessel
is visualized, electrical or chemical cautery (silver nitrate) for hemostasis should be pursued
only on lateral nares and not the septum to prevent perforation. Anterior nasal packing should
be applied for refractory bleeding. Packing failure can be explained by inadequate placement
or anatomic deformity such as a deviated septum or nasal airway obstruction by tumor or
polyp. In these patients, a careful endoscopic examination under general anesthesia should be
considered. We do not recommend blood pressure reduction for the sole purpose of controlling
bleeding. Nevertheless, one must assess signs of hemodynamic instability and necessity of
volume resuscitation.
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2.2. Posterior epistaxis
Posterior nosebleeds carry the highest risk of significant hemorrhage. Patients with persis‐
tent bleeding in spite of conventional treatment should be evaluated for a posterior bleeding
source. Approximately 10% of bleeds occur posteriorly, along the nasal septum or lateral na‐
sal wall. The blood supply includes the external carotids through the sphenopalantine
branch of the internal maxillary artery. Bleeding enters the nasopharynx and oral cavity,
placing the patient at a high risk of respiratory compromise [8, 9]. Concordantly, the man‐
agement of a posterior bleed is more complicated. Posterior nasal packing is prone to im‐
pairing oxygenation. With heavy bleeding, electrocautery and then silver nitrate can aid
hemostasis [10]. Both interventions carry a risk of septal perforation; however, electrocau‐
tery is easier to apply than silver nitrate during heavy bleeding [11]. It is recommended that
an ear, nose, and throat specialist (ENT) be consulted for placement of an inflatable balloon
or a 12–14 French Foley catheter for posterior packing.
At times, posterior gauze packs can be introduced through the mouth and retracted back into
the nasopharynx, thus providing tamponade in the area of choanae and the sphenopalantine
foramen. When conservative measures fail, embolization or surgical ligation of the offending
vessel may be necessary. If surgical ligation by an otolaryngologist fails, patients can be referred
to an interventional radiologist for angiography and embolization.
2.3. Postoperative neck hematoma
The diagnosis of a postoperative hematoma is based on clinical exam, CT head and neck
imaging, and subsequently confirmed with needle aspiration. Hematomas of clinical signifi‐
cance could be presented acutely or in a subacute timeline post procedurally. Obstructions of
the airways occur as a consequence of edema and/or direct compression of the airway. An acute
presentation requires a focus on airway management, whereas chronic hematomas may be a
nidus to infection. If the airway is obstructed, the method of intubation is dictated by the degree
of airway edema and extent of previous surgery. Hematomas can also be decompressed by
either aspiration or releasing surgical staples. If the hematoma is due to an arterial bleed, it
can only be stopped by direct digital pressure or clamping. These patients should be evaluated
surgically.
3. Approach to Lower Airway Emergencies
Tumors of the tracheobronchial tree and mediastinum can cause respiratory failure and ICU
admission. Although primary tumors of the trachea are rare [12], mediastinal, primary lung,
and metastatic lesions can cause a multitude of clinical symptoms. If not addressed promptly,
morbidity and mortality can be significant. Diagnostic and therapeutic modalities are now
available offering bronchoscopic and, if needed, surgical approaches to expedite and minimize
patient complications. Approximately 20–30% of primary lung cancers can be presented with
central airway disease and its sequelae [13] such as atelectasis, hemoptysis, central airway
obstruction (CAO), and postobstructive pneumonias.
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3.1. Hemoptysis
Although some of the most common causes of hemoptysis include bronchitis, bronchiectasis,
and airway trauma, we will be focusing on neoplastic causes. The underlying cause is either
due to endoluminal disease (primary or metastatic), distal invasive disease (including those
of infectious etiology), and coagulopathy or as consequences of systemic disease (i.e., throm-
bocytopenia and drug induced injury). Approximately 20% of lung cancer patients will
experience hemoptysis throughout their disease progression [14] with case series reports of
up to 3% having massive hemoptysis [15].
Aside from neoplastic hemoptysis, other causes, such as heart failure, pulmonary tuberculosis,
lung abscess, coagulopathic, and iatrogenic (airway interventions) should be in the list of initial
differential diagnosis. Hemoptysis is frequently attributable to bronchogenic carcinoma;
however, massive hemoptysis is usually due to squamous cell carcinoma (e.g., centrally located
tumors) [16].
3.2. Diagnosis and management
Hemoptysis can be presented with clinically insignificant streaks or can be catastrophic. It can
include severity that is so burdened by fulminant bleeding that it impairs ventilatory capacity.
It is often in these scenarios that require ICU care, if escalation had not already been established.
The initial approach includes quantification of the amount of blood loss as to help assess the
risk of respiratory failure and asphyxiation. There is no universally defined volume of
hemoptysis to define as massive. However, volumes exceeding 200 cc/h or 600 cc in 24 h [15]
are volumes large enough for expeditious diagnostic and therapeutic intervention. In large
volume hemoptysis, airway protection becomes paramount and intubation is usually neces-
sary. Regardless of the volume, hemoptysis is clinically considered massive when patients
become difficult to ventilate (regardless of underlying morbidity) or if they demonstrate
hemodynamic instability [17].
The initial precautions and interventions to massive life-threatening hemoptysis are universal.
This includes maintaining head of the bead (HOB)>30 degrees, monitoring for hemodynamic
instability, airway protection, and ensuring oxygenation. Patients should be positioned in the
dependent position to preserve the nonbleeding lung from pooling or blood spillage. The
objective is to identify the source of bleeding. Frequently life-threatening hemoptysis warrants
bronchoscopic evaluation with balloon tamponade/endoluminal ablation.
In malignant hemoptysis, chest radiography helps illustrate lunch parenchyma. Aside from
identifying masses and cavitations, radiographs are superseded by multidetector CT (MDCT).
The CT helps visualize abnormal arteries, information which is critical for possible emboliza-
tion. While a diagnostic evaluation as to the source includes these investigational modalities,
emergent bleeding in the ICU deems a patient too unstable for transport. Should the history
and or radiographic imaging not be available, emergent intubation preferably via broncho-
scopy should be completed to isolate the nonbleeding bronchus [18]. Nevertheless, identifying
the cause of hemoptysis in an emergency should overlap the therapeutic interventions and
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must not be a cause of delay. Priority should be taken to identify which lung, or if both, the
bleeding is originating from. Admittedly, a medical history and physical exam is not exten-
sively helpful in identifying the location of bleeding. History should thus be succinct and
oriented at cardiopulmonary, infectious, coagulopathic, and infectious etiologies.
Attention should be paid to any role in coagulopathy reversal, necessity of blood product
transfusion, and assessing oxygenation with blood gas analysis. Moreover, large-volume
hemoptysis is a state of volume depletion, and aggressive intravenous fluid replenishment
should be considered if clinically feasible. Also, there is no optimal ventilator setting for
massive hemoptysis.
3.3. Bronchoscopy
In an emergent setting, patients should be intubated (with a large bore endotracheal tube),
especially if patients will inevitably need bronchoscopy. Bronchoscopic evaluation for
hemoptysis is often laden with blood and/or clots forming debris that requires the intensivist
to retract, clean, and reinsert the bronchoscope. Also, for clearer visualization, large-volume
lavage can risk oxygenation, highlighting the importance of keeping a patient intubated. Both
flexible and rigid bronchoscopies have a role in massive hemoptysis; however, with a rigid
bronchoscope, suctioning capabilities are greater, as are the therapeutic interventions.
Arteriography for persistent hemoptysis is very useful, as embolization of a bleeding artery is
often therapeutic [19, 20]. This is completed by an interventional radiologist in a procedure
suite. If hemoptysis has temporarily ceased, we remind the reader that CT chest imaging is
frequently useful in localizing the source of bleeding. However, patient transfer requires
moderate patient stability and can be time consuming. Tagged red blood cell scanning is not
useful in the emergent setting. Thoracic surgery consultation should be pursued if bleeding
persists despite therapeutic intervention.
Diagnostic bronchoscopy will also aid in identifying any endoluminal/lobar source, thus
dictating the necessary intervention. Should a central bleeding lesion be found during the
initial survey, isolation of the nonbleeding side (as highlighted earlier) is recommended as to
prevent aspiration of blood into normal parenchyma. Insertion of an endoluminal bronchial
blocker (Arndt® Blocker) for initial airway tamponade has utility for prevention of such an
event [21]. Once the endobronchial blocker is inserted, the balloon should be kept inflated for
at least 24 h before assessing rebleeding. In addition to balloon tamponade, other interventions
include cold lavage, cryotherapy, and ablative therapy. Topical vasoconstrictors, such as
epinephrine, can also be applied to help slow bleeding.
Compared to flexible bronchoscopy, the larger lumen of the rigid bronchoscope facilitates a
greater ability to control bleeding while facilitating ablative therapies, and is discussed in a
later section in this chapter (see “Central Airway Obstruction: Immediate Bronchoscopic
Ablative Therapy”). If an endobronchial blocker is not available, direct bronchoscopic-guided
single-lung intubation may be required until further intervention is amenable. This is done by
inserting an endotracheal tube in the main stem bronchus of the nonbleeding lung to wall off
any blood overflow. Double-lumen intubation allows breaths to be ventilated to both lungs
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but is tenuous in the rapidly bleeding airway in which insertion and position maintenance are
difficult to maintain. Interventional pulmonology consultation is recommended for the
aforementioned potential ablative and/or cryotherapy. Transport to the operating room for
rigid bronchoscopy is recommended [21]. As a summation, massive hemoptysis is a life-
threatening clinical presentation that warrants immediate action and a multidisciplinary
approach. Outlook on treatments options would include endoluminal ablation (argon plasma
coagulation or Nd:YAG laser), emergent radiation for distal masses, bronchial or pulmonary
artery embolization, and/or a combination of all.
4. Approach to Central Airway Obstruction
A central airway obstruction is an airflow obstruction either at the trachea, carina, or main-
stem bronchi. For the intensivist, we outline the malignant etiologies, however, there are
benign, traumatic, and iatrogenic (e.g., tracheomalacia) causes as well. Admission into the ICU
due to CAO is frequently due to an acute-on-chronic decompensation of a compromised
airway. Primary lung tumors are the most common causes of central airway obstruction, most
commonly with squamous cell carcinoma followed by adenocarcinoma [22]. Malignant causes
can also be due to endoluminal, metastatic, lymph node, mediastinal, or, less commonly,
nasopharyngeal disease. Further, we will only concentrate on life-threatening acute CAO.
Malignant CAO is primarily palliative in the setting of advanced disease.
The CAO occurs through three basic mechanisms. Simply put, the airway is obstructed either
by direct invasion, compression, or endoluminal disease. A mixed picture is possible as well.
CAO can develop over months to years; however, those that develop acutely can cause
catastrophic outcomes. Patient presentation varies on the degree of obstruction. Significant
obstruction causing enough luminal narrowing to disrupt airflow is the primary reason for the
sensation of dyspnea. Additional signs and symptoms include cough, localized wheezing,
respiratory failure, stridor, and postobstructive pneumonia [23]. Consideration must be made
about tracheal luminal narrowing at the time of symptoms, such that exertional dyspnea occurs
at about 8 mm of narrowing and symptoms at rest occur at 5 mm [22]. Obstruction can occur
in primarily three anatomical variations, defined by the location of mass effect.
One should be prompted to consider CAO in difficult to oxygenate patients with an acute onset
of wheezing, stridor, or tachypnea. Oxygenation and ventilation should be prioritized and
patients must be assessed for the necessity of ventilator support. We recommend pursuit of
the establishment of a secure airway before imaging. If airway obstruction is causing almost
definite respiratory failure, cricothyrotomy, tracheostomy, or retrograde intubation may be
necessary [24, 25]. Often times in the acutely decompensating patient, rigid bronchoscopic
intubation although ideal may not be immediately available. Naturally, larger-diameter
endotracheal tubes are preferred. Fiberoptic intubation may be of role, although availability
is institution dependent [26]. Intervention should thus be focused on airway patency. There is
no role of spirometry in the diagnosis of acute CAO. Also, choice of induction anesthesia is an
important consideration, as a moderate amount of sedation is usually required for rigid
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bronchoscopic intubation. When paralytics or heavy sedatives are used, the already compro-
mised airway can further occlude. Preoxygenation in these instances is of prime importance,
and at times the addition of a mixture of helium and oxygen (known as heliox) as a bridge to
intubation or definitive treatment is useful in providing laminar flow [27]. Overall, we
recommend paralytics be used as a last resort as intubation can be irreversibly compromised
if the airway is lost.
Decompensation could also occur with acute bleeding, swelling and/or additional secretions
occluding an already narrowed lumen. Clinical parameters such as hypoxia and hypercapnia
may not be of much guidance and may misdirect clinicians’ initial index of suspicion.
Although initial evaluation of a patient’s clinical presentation with medical history and
physical exam is pertinent, obtaining relevant imaging in addition to bronchoscopic consid-
eration is central to the management of CAO. Chest radiographs are often the first illustrations
attained but they provide little information to the depth and complexity of obstruction. Chest
CT imaging is the modality of choice for providing detailed anatomical information that plays
a relevant role in formulating a management plan.
4.1. Interventional bronchoscopy
The institutional availability of interventional bronchoscopy is expanding, as is the role in acute
CAO management. Direct bronchoscopic visualization can preclude CT imaging, as direct
visualization may provide an accurate diagnosis and anatomic obstructive characteristics
faster. Not only is bronchoscopy diagnostic, it is primarily considered therapeutic for foreign
object retrieval and suctioning of secretions or blood [28]. Ost et al. demonstrated that
interventional procedures have been shown to have 93% technical success, where 48% of
subjects experiencing improved dyspnea, and a 3.9% complication rate (Table 1) [29].
Malignant Nonmalignant
Primary endoluminal carcinoma
Bronchogenic
Adenoid Cystic
Mucoepidermoid
Carcinoid
Metastatic carcinoma
Bronchogenic
Renal Cell
Thyroid
Sarcoma
Melanoma
Laryngeal carcinoma
Esophageal carcinoma
Tumors of the mediastinum
Lymphadenopathy
Lymphadenopathy
Sarcoidosis
Relapsing polychondritis
Granulation tissue
Hamartomas
Papillomatosis
Airway stents
Artificial airways
Mucus pluging
Blood clot
Granulomatos disease
Goiter
Webs
Table 1. Diseases causing central airway obstruction.
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4.2. Rigid bronchoscopy
A rigid bronchoscope (Figure 1) is pivotal for acute intraluminal CAO for stenting, dilation,
and coring. There are a plurality of techniques and devices available; however, the objective is
universally oriented at airway patency. In addition, interventional procedures for CAO also
provide improvement in palliative symptoms such as exercise tolerance and dyspnea [30]. The
interventional modalities vary depending on institution, available resources, operator prefer-
ences, and location of CAO. Dilation, via balloon or mechanical coring, can be used for both
extraluminal and endoluminal tumor burden. Dilation with a rigid bronchoscope can be
advantageous as it can also be simultaneously utilized for patient intubation. CAO with high
risk of perforation or bleeding may be sequentially dilated.
Figure 1. Rigid Bronchoscope (picture courtesy, Emil Abramian MD).
4.3. Immediate bronchoscopic ablative therapy
Immediate ablation is highly effective at clearing CAO. However, ablation usually requires
coupling with a second intervention, such as stenting. Ablation primarily consists of argon
plasma coagulation (APC) and electrocautery. Extraluminal obstructions are managed with
dilation and stenting. These procedures have been found to have similar outcomes, and
modality is dependent on the proceduralist’s preference [31]. Eventual maintenance of airway
patency is usually obtained by multiple interventional approaches (e.g., tumor coring and
subsequent stenting) [28]. Reopening of the airway (>50%) was achieved in the majority of
cases in a recent multicenter study [29].
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Laser therapy (Nd:YAG, argon, excimer) is a promptly effective therapy for intraluminal CAO;
however, it is not suitable for long lesions (>4 cm). Laser ablation essentially results in de-
struction of the obstructing vascularizing vessels and ends with subsequent obstruction
extraction. Electrocautery is an alternative to laser therapy but the direct thermal administra-
tion causes a risk for airway fire, and is only suitable for endoluminal disease.
Argon plasma coagulation (APC), another noncontact thermal ablative, is highly effective for
vascular lesions with a high tendency to bleed, or those that are nestled in airway bifurcations.
In contrast to laser therapy, argon gas is electrically coupled to create electrical current that
creates target tissue destruction through a grounding principle. As such, flat lesions and lesions
at airway bifurcations that are difficult to visualize are effectively managed with APC. The
naturally coagulant effects of argon are also advantageous for achieving hemostatis. Moreover,
obliteration of granulation tissue surrounding metallic stents is safely approached with APC.
Exercising caution with APC in a patient with high-FiO2 requirements (risk of airway fire) is
recommended.
Risk for airway fire is elevated in patients with FiO2 requirements greater than 40%, and thus
cryotherapy is an advantageous technique for endoluminal obstructions. Cooling agents such
as nitrous oxide and liquid nitrogen are used to repeatedly freeze and thaw tissue, ultimately
rendering tissue nonviable. Also, the resistance of cartilage and fibrous tissue to thermal
conductive effects of cryotherapy accounts for its safety. Efficacy has been shown for reduction
in bleeding and hemoptysis [32]. Effects of cryotherapy, however, are temporary and delayed,
and should not be used in an emergent CAO. Moreover, cryotherapy should not be utilized
for extrinsic compression.
There is no role of photodynamic therapy in emergent CAO management.
4.4. Airway stenting
There are various materials and manufacturers of airway stents. Silicone stenting after an initial
ablative procedure has been shown to safely maintain airway patency [33]. It is preferred over
traditional metal stents that are commonly associated with airway perforation, granulation
tissue formation, and bleeding. Popularly used and commonly known as the Dumon™ stent
(Novatech), named after Jean Francois Dumon, it is a studded silicone stent that comes in a
straight and Y-shaped mold (for saddling on carinal placement). The length and caliber of the
stent is determined periprocedurally and is sized by the operant. Although stents are relatively
thermoresistant and inexpensive, they do have the potential to migrate. Combined silicone
and metal stents, known as hybrid stents, are frequently used but are more expensive. They
combine the benefits of silicone and metal to give optimal compressive resistance while
minimizing granulation tissue and perforation.
Another variant, the radioopaque Polyflex silicone stent (Boston Scientific) has synthetic
threads that allow for stent flexibility and optimal thinness. These stents, however, have a
greater risk of stent migration than the studded Dumon stent [34]. Finally, Dynamic Y stents
are more anatomically forgiving, as they have anterior rings that mimic the tracheal lumen but
the long length can impair mucous clearance. Overall, safety is high for these therapeutic
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interventions and complications such as pneumothorax, airway trauma, infection, stent
migration, respiratory compromise, and death are low [35].
5. Postobstructive Pneumonia
Despite the paucity of literature outlining the management of postobstructive pneumonia, it
is quite frequent in those with bronchogenic carcinoma. Most typically seen with small cell
and squamous cell carcinomas, it can be caused by endobronchial involvement by a tumor or
through extrinsic compression and parenchymal involvement. Other malignant causes include
metastatic colon, breast, and renal cancers. Diagnosis is crucial as one must consider that the
mortality of pneumonia is worse in those with underlying malignancy. Prolonged postob-
structive pneumonia may lead to cavitation and necrosis. The intensivist should have a high
degree of suspicion for postobstructive pneumonia in patients with radiographic evidence of
atelectasis or mucous plugging. Diagnosis should be established and luminal patency should
be estimated via CT imaging or endobronchial ultrasound (EBUS).
Patients with postobstructive pneumonia tend to have a longer duration of pulmonary
symptoms, compared to those with uncomplicated community-acquired pneumonia. Also,
rises in serum biomarkers such as the white blood cell count and procalcitonin are frequently
not be observed. Those presenting with fever, however, have shown to provide greater
bacteriologic yield [36–38]. Mortality, however, is higher [39].
Patients may present with signs and symptoms of septic shock (e.g., hypotension and tachy-
cardia) or can be as uncomplicated as cough or dyspnea. Prior to any intervention, early
antibiotic coverage must be initiated with appropriate coverage for Gram negative bacilli
(Enterobacter cloacae, Aacinetobacter sp, and Pseudomonas aeruginosa), respiratory anaerobes,
Staphylococcus aureus [40]. Patients can also be iatrogenically inoculated through interventional
procedures, such as airway stent placement. The virulence of the inoculum is unclear; however,
they may contribute to impaired innate airway mucous clearance.
The microbiota of postobstructive pneumonia appears to be polymicrobial and isolating an
organism can be difficult. If microbiologic speciation is critical or if infection must be differ-
entiated from alternative pathologic process, bronchoscopic sampling has greater yield than
sputum culture [41]. Tumor debulking and airway reestablishment through interventional
bronchoscopic techniques (argon plasma anticoagulation) help reduce mass effect and
facilitate antibiotic penetration. Although it was studied as a palliative form of tumor burden,
de Aquino Gorayeb et al. were able to demonstrate an improvement in performance status and
postobstructive pneumonia (80% response) to high-dose brachytherapy [42].
If radiographic imaging is unavailable, intraprocedural empiric treatment should be consid-
ered, prior to therapeutic aspiration. Additionally, decanting pus from one airway still may
provide a very brisk systemic response that must be treated aggressively with clinically
appropriate volume resuscitation, in addition to aforementioned antibiotics. Antibiotic
timeline must be tailored to the appropriate organism. The trachea, bronchus, and pulmonary
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parenchyma provide a wide array of complications during the care of an oncologically
critically ill patient. A judicious, yet timely systematic approach will ensure that the above
aforementioned complications can be quickly dealt with.
6. Approach to Pneumothorax
Pneumothorax is defined as air in the pleural space. A common condition observed in the
patients with malignancy and is more attributable to primary lesions than metastatic disease
[43]. Pneumothorax can complicate an already deteriorating patient that may have subtle
findings or can potentially require emergent intervention.
Traumatic
Blunt force
Iatrogenic
Thoracic surgery
Central venous catheter insertion
Transthoracic biopsy
Mechanical ventilation
Spontaneous
Primary
Secondary
Neoplastic (primary or metastatic)
Infectious
Interstitial lung disease (idiopathic, medication induced, radiation induced)
Chronic obstructive pulmonary disease
Cystic fibrosis [45]
Table 2. Classification of pneumothorax.
Here, we classify pneumothorax into primary spontaneous pneumothorax (PSP), secondary
spontaneous pneumothorax (SSP), and traumatic pneumothorax. PSP occurs in patients
without underlying lung disease. Secondary spontaneous pneumothorax is attributable to an
underlying pulmonary disorder. Traumatic pneumothorax can be due to blunt physical trauma
or from iatrogenic causes, such as invasive procedures and radiation therapy. Secondary
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spontaneous pneumothorax has shown an association with higher morbidity and mortality
than primary spontaneous pneumothorax [44] (Table 2).
Iatrogenic pneumothorax is most common in hospitalized patients. Increasing incidence has
correlated with the incidence of invasive diagnostic and therapeutic procedures, such as
transthoracic lung biopsy and central venous catheter (CVC) insertion. Transthoracic needle
aspiration is responsible for 45.7% and CVC in 24.8% [46]. Image guidance with CT for
transthoracic biopsy reduced rates to 20% [47], although rates can vary significantly by
institution. Currently, there is conflicting data whether smaller lesions or those with longer
anatomic depth are associated with higher rates of pneumothorax [48]. As a complication of
mechanical ventilation, pneumothorax carries an increase in morbidity and mortality, and has
the highest risk of pneumothorax in the intensive care unit (ICU), particularly with the use of
positive-end expiratory pressure [49, 50]. Rates of barotrauma have been noted to be as high
as 15% [51].
Secondary spontaneous pneumothorax (SSP) is seen in both primary and metastatic diseases,
regardless of pleural invasion. Tumor pleural involvement can cause cavitation, necrosis, and
subsequent pleural damage. There have been many reports of pneumothorax secondary to
chemotherapy administration [52–54] likely as a consequence of lysis of chemosensitive
lesions.
Tension pneumothorax, as seen with mechanical ventilation or cardiopulmonary resuscitation,
is a medical emergency. The incidence has not been definitively established, and statistical
analysis is in its infancy [55]. Reports in adult ICUs have been as high as 3% [56]. Suspicion for
such should be high when there is patient decompensation after known pneumothorax. It is
suggested that delaying intervention until radiography has contributed to mortality [57]. This
is a medical emergency and requires immediate mechanical decompression even before
confirmation with imaging [58].
Bronchopleural fistula (BPF) is the presence of a significant, persistent air leakage after tube
thoracostomy. Incidence has been reported up to 4.5% [59]. Occurrence of BPF has been
reduced in recent years due to management of patients at risk (e.g., acute respiratory distress
syndrome) with low tidal volume ventilation protocols [60, 61]. Despite this, knowledge of
BPF is necessary for patients with a persistent pneumothorax and/or status post lung resection.
The mechanism involves airway disruption or alveolar rupture and can be due to mechanical
volume overdistension [62, 63], elevated transpulmonary pressures [64], pleural trauma from
an invasive procedure, or spontaneous rupture. Additional causes include inappropriate right
main bronchus intubation and severe sepsis. Animal studies have demonstrated that excessive
volume, rather than elevated airway pressures have been linked to alveolar rupture. Hence
the term volutrauma, as opposed to barotrauma, more appropriately describes alveolar rupture
[63]. Nevertheless, elevated transpulmonary pressures can play a major role in alveolar
rupture [64]. Current recommendations, further outlined under Management, involve low-
volume ventilation (≤6 mL/kg of predicted body weight), close monitoring for auto-PEEP, and
avoidance of excessive hyperventilation [61].
Oncology Critical Care14
6.1. Pathophysiology
In a normal lung, negative intrapleural pressure throughout the entire breathing cycle is
maintained in the pleural space relative to the atmosphere, allowing for physiologic lung
expansion, known as elastic recoil [65]. Transpulmonary pressure between lung alveoli and
the pleura is disrupted due to alveolar permeability. This results in permeation of alveolar gas
into low-resistance anatomic surfaces, such as the mediastinum, peritoneum, and pleural
space. On inspiration, air that has translocated from alveoli enters directly to pleural cavity [66].
In tension physiology, once the nidus has occurred, the pleural cavity pressure equalizes with
the chest wall environment causing a reduction of transpulmonary pressure, reducing vital
capacity [67]. In the healthy awake adult, compensatory intrapleural pressures rise in attempt
to compensate for tension pneumothorax. There is significant impairment of this with patients
on mechanical ventilation, who usually are sedated. With positive pressure ventilation,
inspiratory pressures are significantly elevated, creating an exaggerated pressure gradient.
This is worsened from environmental air compressing lung parenchyma and distorting
intrapleural pressure, risking mediastinal shift to the opposite lung and diaphragmatic
depression. Alveoli may leak air into the pleura during inspiration only, creating a one-way
valve effect, causing accumulation of pleural air. Rising pleural pressure can progress to affect
nearby structures, resulting in ipsilateral lung deflation, mediastinal shift, and a rapid
reduction in cardiac output [67].
6.2. Measurement
Assessing the size of a pneumothorax guides practitioners as to pursuing conservative versus
invasive management. Light’s index [68, 69] measures the percentile of pneumothorax:
Light’s index = 100% − (diameter of collapsed lung3/diameter of hemithorax3) (100%). Light’s
index is helpful for quantifying reexpansion of lung after intervention [68, 69].
An alternative method involves measuring the average of the intrapleural distance at the level
of the apical, mid-thorax, and basal levels. According to the British Medical Society, a “large”
pneumothorax is defined as having >2 cm lung margin from the chest wall on roentgenogram
[49]. Those classified as large warrants surgical decompression. It is important to note,
however, that clinical symptoms outweigh measurement indices on interventional decision
making.
6.3. Physical examination
Patients that develop secondary spontaneous pneumothorax present with varying degrees of
severity dependent on the rate and volume of air accumulation, patient’s age, status of
mechanical ventilation, and baseline pulmonary function at the time of diagnosis. Because the
pathophysiology involves a reduction in vital capacity, a predisposed lung can be presented
with dramatic constellation of symptoms. Dyspnea, anxiety, and chest discomfort are common
presenting symptoms [70]. Physical exam findings can include diminished breath sounds,
increased manual percussion resonance on the ipsilateral affected lung, subcutaneous
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emphysema (Hamman’s sign) [71], and tracheal deviation. Clinical signs can include tachyp-
nea, oxygen desaturation, and increased work of breathing.
For the mechanically ventilated, frequent signs of tension pneumothorax include an acute
onset of elevated pulmonary pressures (both peak and plateau) and hypotension [72].
Diagnosis includes obtaining chest radiography, which is demonstrated with a pleural line
that is absent in lung markings beyond the line. However, it may take over 24 h for evidence
after insult. A deep sulcus sign may only be the only radiographic evidence of pneumothorax,
when seen on a supine image. Air collects basally, as opposed to the lung apex, causing a
deepening of the costophrenic angle [73]. Diaphragmatic inversion with tracheal deviation is
suggestive, although not pathognomonic, of tension pneumothorax [72]. Even with anatomic
deviation, appropriate diagnosis was missed approximately half the time [74].
6.4. Management
American College of Chest Physicians (ACCP) guidelines provide recommendations based on
patient stability and size of pneumothorax. Supplemental O2 should be considered universal-
ly [44, 75], with caution taken for patients with chronic obstructive pulmonary disease and a
proclivity to retain carbon dioxide. Small, stable pneumothoraces may be conservatively
observed with appropriate follow up. Large pneumothoraces require hospitalization and
needle or tube decompression.
Supplemental oxygen improves the rate of pleural air resorption through reduction of arterial
nitrogen content. Reduced arterial nitrogen content creates a larger pleural space gradient,
thus accelerating resorption of pleural air [44, 76].
Drainage is usually indicated in most patients with secondary spontaneous pneumothorax
[44]. To further extrapolate indications for drainage, those who have symptomatic “large” SSP
(as outlined earlier), the risk of resolution is outweighed by progressive risk of pleural
compromise, and thoracostomy is warranted [77]. Small SSP (<2 cm from chest wall) can be
managed with small bore chest tube. Asymptomatic patients with <1 cm from chest wall
pneumothoraces can be managed conservatively with supplemental oxygen and serial chest
radiography. Tube thoracostomy, when compared to needle decompression, has shown greater
rate of success [44]. If a needle aspiration yields greater than 2.5 L of air, chest tube is indicated
due to suspected air leak. Intervention can be guided with sonographic or fluoroscopic imaging
if necessary.
Chest tube should be connected to water seal device and may be connected to a one-way
Heimlich valve or low suction to aid reexpansion of lung [44]. Chest tube thoracostomy was
successful in 78.1% of cases, and was not dependent on tube size [46]. If air leak has resolved
and the lung has re-expanded on radiograph at least 12 h after last documented leak, the chest
tube can be clamped, and removed after approximately 24 h [75]. Long term stabilization and
pneumothorax recurrence may warrant intervention for prevention (e.g., pleurodesis) [44].
Persistent air leakage after 4 days of bronchopleural fistula after tube thoracostomy favors
intervention over expectant management for spontaneous closure [44, 75, 77]. If a patient is
mechanically ventilated, it is recommended to reduce tidal volume and airway pressures as
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tolerated, if not already done so [56]. Reducing overdistention of alveoli and development of
intrinsic peep helps reduce transpulmonary gradients. This is achieved through the following
maneuvers: Increasing inspiratory to expiratory ratio (I:E) through inspiratory flow control,
decreasing tidal volume to ≤6 mL/kg predicted body weight, and adjusting the amount of
ventilator driven patient breaths.
Bronchoscopic maneuvers such as deployment of endobronchial stenting, bronchoscopic
valves [78], coiling [79, 80], injection of sclerosant, or laser coagulation has been utilized with
efficacy [81–85].
Possible interventions include video-assisted thoracoscopic surgery (VATS) with mechanical
or chemical pleurodesis, or VATS with resection of blebs. Additional chest tube placement or
bronchoscopic intervention with the intent of sealing air leak is not recommended [75].
Chemical pleurodesis through tube thoracostomy is not recommended as well, although
patients with poor surgical candidacy, current recommendations are talc slurry or doxycycline.
Blood patch pleurodesis has shown outcomes with variable success [86, 87]. This is performed
by instilling the patient’s own venous blood (50-100 mL) into the pleural space through a chest
tube.
Overall recurrence of secondary spontaneous pneumothorax is frequent [49]. We therefore
recommend consideration for recurrence prevention through two options; surgical and
chemical. Surgical options include VATS or open thoracotomy, depending on independent
practitioner preference and patient candidacy. Open thoracotomy has shown lower recurrence
rates but has higher blood loss and longer recovery times, and therefore, VATS with pleural
obliteration is preferred [44, 75, 88]. Pleural obliteration can be achieved through pleurectomy,
talc administration, and abrasion with gauze [89–91]. Chemical pleurodesis through tube
thoracostomy has been shown to reduce recurrence of SSP, however success ranges 78–91%
versus 95–100% with surgical intervention [44].
7. General Approach to Pleural Effusions
Approximately two-thirds of massive pleural effusions are associated with an underlying
malignancy, [92] the majority of which present with 500–2000 mL of pleural fluid accumulation.
Fluid collection can be serous, hematogenous, or serosanguinous. Of all exudative pleural
effusions, pneumonia and malignancy are the two leading causes [93, 94]. In males, lung cancer
is the most frequent metastatic pleural malignancy, breast cancer is most frequent in women
[95, 96], and in up to 15% of cases, is unknown [97]. Often times recurrent, the responsible
mechanism for pleural fluid accumulation is due to hilar and mediastinal lymphatic obstruc-
tion or seeding [92, 98]. Isolation of malignant cells in pleural fluid indicates a malignant
pleural effusion (MPE). The development of hemothorax is due to the role of tumor angio-
genesis, tumor invasion into blood vessels, or direct humoral capillary permeability [99].
Malignant pleural effusion (MPE) is a frequent complication of advanced malignancy, and
carries a poor prognosis, affecting more than 150,000 people annually in the U.S. [100]. Median
survival, depending on underlying malignancy, is less than 6 months once a diagnosis of MPE
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is made [96, 100]. MPE is diagnosed with malignant cells found in pleural fluid, which is often
difficult to obtain. Pleural fluid analysis, in conjunction with the clinical history, is also
sufficient to substantiate a diagnosis. Although in the ongoing years, the Light’s criteria has
faced scrutiny for excluding additional biomarkers (e.g., amylase) and including the closely
correlated serum and pleural fluid lactate dehydrogenase (LDH) [101], it remains the mainstay
of differentiating a transudative versus an exudative pleural effusion.
Light’s criteria deems a pleural fluid as exudative if at least one of the following criteria are
met [102]:
Pleural fluid protein/serum protein ratio greater than 0.5,
Pleural fluid LDH/serum LDH ratio greater than 0.6, or
Pleural fluid LDH greater than two-thirds the upper limits of the laboratory’s normal serum
LDH.
Amylase-rich pleural fluid can be suggestive of acute pancreatitis, esophageal rupture, or
malignancy [103]. Recent studies have suggested that elevated serum lactate dehydrogenase
to pleural fluid adenosine deaminase has been predictive of malignancy [104].
It is important to note, however, alternative causes of large pleural effusions in the setting of
malignancy, such as congestive heart failure, venous thromboembolism, toxic effects of
chemotherapy administration [105], radiation [106], low protein states, and pneumonia.
Cytologic analysis of pleural fluid helps differentiate the underlying cause. Obstruction of the
thoracic duct may also cause chylothorax and is suggested by pleural fluid triglyceride levels
above 110 mg/dL (Table 3) [107].
Straw – Transudative process
Pus – Empyema
Red – Hemothorax
  Pulmonary infarction
  Postcardiac arrest
  Iatrogenic (post procedure)
White – Chylothorax
Black – Aspergillosis
Ammonia – Urinothorax
Table 3. Qualitative description of pleural fluid.
Complicated parapneumonic effusions are often culture negative, have poor response to
systemic antimicrobials, and may be loculated. Diagnosis is through pleural fluid analysis and
utilization of the following criteria: pleural fluid pH less than 7.20, glucose level less than 60
mg/dL, and LDH > 1000 IU/L [108]. Meeting the aforementioned criterion renders a poor
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prognosis [109]. Complicated parapneumonic effusions warrant chest tube placement that
otherwise runs the risk of progression to thoracic empyema [110]. The majority of organisms
isolated through fluid culture or Gram stain consist of staphylococci and anaerobes such as
Fusobacterium, Peptostreptococcus, Bacteroides fragilis, and Prevotella species [111, 112]. Long-term
sequelae of unresolving empyema, hemothorax, and surgical manipulation may result in a
trapped lung. Trapped lung occurs when reexpansion of atelectatic lung is impaired due to a
fibrinous peel overlying visceral pleura, creating a chronic pleural effusion. Lung entrapment,
in turn, is an unexpandable lung due to active malignancy or infection [113, 114]. For patients
with significantly trapped lung, pleurodesis can be deferred.
Chemotherapy associated with large-volume effusions include methotrexate, procarbazine,
cyclophosphamide, mitomycin, bleomycin, and IL-1 (Table 4) [106].
Malignancies associated with malignant
pleural effusions [62]
Indirect causes of pleural effusions
(paramalignant)
Lung 37.5%
Breast 16.8%
Lymphoma 11.5%
Genitourinary 9.4%
GI tract 6.8%
Local tumor effect
Trapped lung
Chylothorax
Lymphatic obstruction
SVC (superior vena cava) syndrome
Pulmonary embolism
Hypoalbuminemic state
Chemotherapy/radiation therapy (incomplete)
Tumor necrosis factor
Interleukin-2
Methotrexate
Bleomycin
Cyclophosphamide
Table 4. Malignant and indirect (paramalignant) causes of effusions.
Severity in symptoms is dependent on residual lung function, acuity in rate of fluid accumu-
lation, and whether or not the patient is on mechanical ventilation. Large pleural effusions are
often symptomatic and results in reduced chest wall compliance and lung volume [115]. These
include orthopnea, cough, dyspnea, and fever. Examination of the affected lung may include
diminished breath sounds, tactile fremitus, and crackles. Tracheal deviation may also be a
presenting finding with larger-volume effusions. Diagnosis of pleural effusion is suspected
with physical examination and confirmed radiographically. Treatment can be either palliative
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or aimed at improving survival. Reaccumulation of MPE can worsen a patient’s symptoms;
however, in asymptomatic individuals, cost, preference, and functional status should be taken
into account.
Diagnostic and therapeutic considerations with large volumes are first achieved with thora-
centesis [116]. Pleural fluid analysis helps determine between transudative or exudative
effusions and may indicate the primary cause [117]. The severity of symptoms and global
prognosis of the patient dictates the necessity of further invasiveness [118]. Recurrence is high
with therapeutic aspiration without pleurodesis incurs a high rate. Thoracentesis is not without
complications, including pneumothorax, empyema, and adhesions [96]. Other procedures
include pleural biopsy, bronchoscopy, pleuroscopy, and video-assisted thoracoscopic surgery
(VATS) with biopsy.
In the setting of clinical acuity, such as hemodynamic compromise, tracheal deviation,
diminishing hypoxemia, or a progressively unstable airway, emergent indication is indicated
for lung reexpansion. Thoracentesis should be performed for relief of symptoms, and chest
tube drainage is recommended for empyema and/or complicated parapneumonic effusions.
If a patient has a very limited lifespan (i.e., <1 month), pleurodesis is less strongly recom-
mended. Aspiration on each occasion should not exceed 1.5 L to avoid reexpansion of
pulmonary edema [119].
Inadequate or improperly draining tubes may warrant decortication. Nearly all patients with
malignant pleural effusion who undergo drainage face recurrence within 30 days [120, 121].
Such patients benefit from pleurodesis, when in consideration of life expectancy. Repeat
thoracentesis is selectively recommended for patients with short life expectancy, as it can lead
to formation of adhesions, mentioned earlier. Repeat aspiration helps palliate symptoms for
the terminally ill, especially with the use of small-bore catheters [122].
Pleurodesis can be done surgically or chemically. Chemical pleurodesis may require a
prolonged hospital stay and carries a small risk of pneumonitis [123]. Thoracoscopic pleurod-
esis is recommended over catheter based [124, 125].
Surgical outcomes are often difficult to achieve due to poor surgical candidacy. Chemical
pleurodesis involves infusion of a sclerosing agent such as talc (poudrage or slurry), 5-FU,
minocycline, bleomycin, and silver nitrate, with talc being the most successful agent for
providing reaccumulation after 1 month [126–128].
Pleurodesis helps achieve lung expansion and reestablishes normal symphysis of visceral and
parietal pleura. The primary mechanism involves inciting a broad spread inflammatory
response, in turn promoting fibrin deposits [129]. Suspected antitumor effects of talc by
induction of apoptosis of cancer cells may also help provide a role in blunting tumor progres-
sion intrapleurally. Bleomycin carries a well-established antineoplastic role [130]. With recent
meta-analyses, both talc poudrage and slurry are equally efficacious with thoracoscopic
technique considered ideal [96].
Alternatives include chronic indwelling catheter placement, which is an increasingly popular
option due to its low risk of infection, displacement, and manageability as an outpatient [131].
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Both talc pleurodesis and chronic indwelling catheters have been shown to be effective initial
treatments for MPE [126]. Indwelling catheters also have a role once a patient develops trapped
lung.
For clinically stable patients with poor response to initial thoracostomy drainage or with
multiloculated effusions, and are poor candidates for surgical intervention, intrapleural tissue
plasminogen activator (tPA) combined with DNase has been a growingly influential therapy,
without additional excess of adverse events [132, 133]. Administration of fibrinolytics or DNase
alone did not improve outcomes [133, 134]. Pleuroperitoneal shunting is an additional option
to consider, especially in patients with trapped lung (Table 5) [100, 109].
Thoracentesis/
thoracostomy
Large pleural effusions. Thoracostomy for chest tube insertion, fibrinolysis, and
pleurodesis.
Pleurodesis Recurrent pleural effusion
Video-assisted
thoracoscopic
surgery (VATS)
Complicated/parapneumonic effusion, pleurodesis, and pleurectomy. Lysis of adhesions,
blebectomy, decortication, lobectomy, and lung volume reduction. Contraindicated in
hemodynamic instability. Less invasive and painful than thoracotomy.
Thoracotomy with
decortication
Major surgery. Full mediastinal visualization. Better for large tumors, close to
mediastinal/vascular structures. Higher risk of complications and estimated blood loss
[101].
PleurX® catheter Can be managed outpatient, role palliative care.
Pleuroperitoneal shunt Exhaustion of alternative options, useful for chylothorax in managing nutritional and
immunologic status.
Table 5. Interventional procedures in management of massive pleural effusion.
8. Approach to Hemothorax
Hemothorax is evident when frank blood is aspirated from pleural space during thoracentesis,
tube thoracostomy, or VATS, and is confirmed when pleural fluid hematocrit exceeds more
than >50% of serum hematocrit concentration. Pleural bleeding can be simplified as being due
to mediastinal or pleural tissue insult. Diagnosis is mainly attributable to mechanical chest
trauma, and its overall incidence has not been well quantified. Nontraumatic hemothorax is
most commonly due to malignancy and is explained by the role of tumor angiogenesis,
invasion into blood vessels, or direct humoral capillary permeability [99]. Not to be confused
with a bloody tap, where the latter instance clears after centrifuge, hemothorax has a propen-
sity to not clot due to continuing defibrination from mediastinal motion. Other causes may be
a consequence of iatrogenic anticoagulation [136], pulmonary embolism causing pulmonary
infarction, or catamenial hemothorax [137, 138]. Surgical manipulation, such as thoracentesis,
bronchoscopic biopsy, mediastinoscopy [139], needle biopsy, and central venous catheter
insertion may also be a cause [140]. Spontaneous hemothorax, i.e., hemothorax without
identifiable cause, is infrequent [141]. Causes are outlined below (Table 6) [75].
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Nontraumatic
  Neoplastic
   Metastatic diseases
   Vascular malignancy
   Bronchogenic carcinoma
   Mesothelioma
   Angiosarcoma
  Coagulopathy
   Anticoagulation
   Thrombocytopenia
   Congenital disorders
 Pulmonary embolism
 Pulmonary infarct
 Vascular
   Arteriovenous malformation
   Aneurysm
   Connective tissue disease
   Aortic dissection
Traumatic
Central venous catheter
Thoracentesis
Transbronchial biopsy
Percutaneous needle aspirate
Pleural biopsy
Thoracic surgery
Table 6. Nontraumatic and traumatic causes of hemorrhagic pleural effusions.
8.1. Imaging
Hemothorax and pleural effusion is not distinguishable on routine chest radiography or
ultrasonography. Presenting history aids index of suspicion helps distinguishing between
hemothorax and pleural effusion. Chest CT imaging blood presents with higher attenuation
than pleural effusion. Later stages of hemothorax can include pleural deposition, thickening,
and loculation [142]. CT imaging is also well associated with determining the necessity of
VATS [143]. Hemopneumothorax is characterized by a pneumothorax with ipsilateral air‐fluid
level. Suspicion for vascular etiologies may warrant CT angiography.
8.2. Management
Outlining the management of a patient with confirmed hemothorax in the intensive care unit
depends on patient stability and prognosis, and spans from supportive care to emergent
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thoracotomy [144]. Goals of care are for blood evacuation to avoid fibrin deposition and
subsequent trapped lung, and the development of empyema [145].
Discontinuation of anticoagulant therapy and correction of any coagulopathy is recommended
if hemothorax is attributable to systemic anticoagulation [145, 146]. Massive hemothorax may
require blood transfusion resuscitation. Blood collection in the pleural space in minimal
amounts may spontaneously reabsorb; however, chest tube drainage is necessary for rapidly
developing hemothorax [27]. Drainage reestablishes parieto-pleural symphysis and creates a
tamponade if the source of bleeding is from pleural rupture. With concomitant pneumothorax,
i.e., hemopneumothorax, drainage is definitively indicated. In contrast to chest tube manage-
ment of spontaneous pneumothorax, large-bore chest tubes should be placed due to the
rapidity of clotting [75, 146, 147].
Thoracotomy is warranted for the hemodynamically unstable and those with massive hemo-
thorax. This constitutes patients with severely rapid exsanguination with retained volume
greater than 500 mL, accumulated output over 1500 mL, or if exsanguination is above 200 ml
per h [139, 148]. Chest tubes can be maintained in the chest wall cavity until the amount of
tube drainage in 24 h is less than 100 mL but removal should not be prolonged to reduce the
risk of infectious inoculation [149]. Residual clotted blood after thoracostomy should be
removed thoracoscopically to reduce the risk of empyema and fibrothorax [150]. Fibrothoraces
that require VATS decortication should be delayed months after initial insult in order to allow
coalescence and stabilization of a fibrin peel [145]. VATS permits safe decortication of adhe-
sions and removal of clotted blood. The role of intrapleural fibrinolytics in the management of
hemothorax is currently in its infancy. VATS has better proven efficacy and shorter Hospitali-
zation stay [135]; however, fibrinolytics are a considerable option when patients are without
underlying coagulopathy but are clinically unstable for VATS [148, 151–153]. Fibrinolytics can
be applied for chemical lysis of intrapleural adhesions, commonly seen with fibrothorax [75].
There is no evidence indicating systemic side effects to intrapleural fibrinolysis. Antimicrobials
early in the treatment of traumatic hemothorax reduce rates of empyema. There is evidence
showing benefit in prophylactic administration spontaneous pneumothorax as well. Initial
antibiotic coverage for empyema should include Staphylococcus and Streptococcus [154].
9. Conclusion
Substantial challenges present themselves in the ICU, with airway compromise being one of
the high priorities. Either caused by primary cancers or secondary metastasis, the upper and
lower airways have very little room for error. Hemorrhaging from or into the nasopharynx,
trachea, and its tributaries can precipitate an inability to ventilate and oxygenate rapidly.
Understanding the anatomical and physiological challenges are the first steps to managing
such complex scenarios. Rapid stabilization with nasal packing and/or protection of ventila-
tory units, via intubation, is an essential task for the intensivist. Subsequently understanding
or having a high index of suspicion as to the origin of respiratory failure helps prevent further
decline in respiratory status. Central airway obstruction requires urgent/emergent advanced
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bronchoscopic evaluation with potential therapeutic intervention. One must be also cognizant
that large pleural effusions (of varying origin) and/or pneumothoraces contribute to the
spectrum of emergencies faced in an oncological critical care unit.
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